Literature DB >> 24148855

Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.

Mathieu Bourdenx1, Anna Nilsson2, Henrik Wadensten2, Maria Fälth2, Qin Li3, Alan R Crossman4, Per E Andrén2, Erwan Bezard5.   

Abstract

A role for enhanced peptidergic transmission, either opioidergic or not, has been proposed for the generation of l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID) on the basis of in situ hybridization studies showing that striatal peptidergic precursor expression consistently correlates with LID severity. Few studies, however, have focused on the actual peptides derived from these precursors. We used mass-spectrometry to study peptide profiles in the putamen and globus pallidus (internalis and externalis) collected from 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine treated macaque monkeys, acutely or chronically treated with l-DOPA. We identified that parkinsonian and dyskinetic states are associated with an abnormal production of proenkephalin-, prodynorphin- and protachykinin-1-derived peptides in both segments of the globus pallidus. Moreover, we report that peptidergic processing is dopamine-state dependent and highly structure-specific, possibly explaining the failure of previous clinical trials attempting to rectify abnormal peptidergic transmission.
© 2013.

Entities:  

Keywords:  MPTP; Mass spectrometry; Parkinson's disease; Peptides; Primate; l-DOPA-induced dyskinesia

Mesh:

Substances:

Year:  2013        PMID: 24148855     DOI: 10.1016/j.nbd.2013.10.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  11 in total

1.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

Review 2.  Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.

Authors:  Krishna D B Anapindi; Elena V Romanova; James W Checco; Jonathan V Sweedler
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Erwan Bezard; Qin Li; Heather Hulme; Elva Fridjonsdottir; Anna Nilsson; Elsa Pioli; Per E Andren; Alan R Crossman
Journal:  J Neurosci       Date:  2020-07-20       Impact factor: 6.167

4.  Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.

Authors:  Garikoitz Azkona; Irene Marcilla; Rakel López de Maturana; Amaya Sousa; Esther Pérez-Navarro; Maria-Rosario Luquin; Rosario Sanchez-Pernaute
Journal:  Mol Neurobiol       Date:  2014-04-05       Impact factor: 5.590

5.  Anatomo-proteomic characterization of human basal ganglia: focus on striatum and globus pallidus.

Authors:  Joaquín Fernández-Irigoyen; María Victoria Zelaya; Teresa Tuñon; Enrique Santamaría
Journal:  Mol Brain       Date:  2014-11-18       Impact factor: 4.041

6.  Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.

Authors:  Anna Migdalska-Richards; Wai Kin D Ko; Qin Li; Erwan Bezard; Anthony H V Schapira
Journal:  Synapse       Date:  2017-03-17       Impact factor: 2.562

Review 7.  Opioid system in L-DOPA-induced dyskinesia.

Authors:  Jing Pan; Huaibin Cai
Journal:  Transl Neurodegener       Date:  2017-01-17       Impact factor: 8.014

8.  Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.

Authors:  Carl Rosenblad; Qin Li; Elsa Y Pioli; Sandra Dovero; André Slm Antunes; Leticia Agúndez; Martino Bardelli; R Michael Linden; Els Henckaerts; Anders Björklund; Erwan Bezard; Tomas Björklund
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 9.  Experimental Models for Aging and their Potential for Novel Drug Discovery.

Authors:  Jaume Folch; Oriol Busquets; Miren Ettcheto; Elena Sánchez-López; Mercè Pallàs; Carlos Beas-Zarate; Miguel Marin; Gemma Casadesus; Jordi Olloquequi; Carme Auladell; Antoni Camins
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

10.  The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients.

Authors:  Tommaso Nuzzo; Daniela Punzo; Paola Devoto; Elena Rosini; Silvia Paciotti; Silvia Sacchi; Qin Li; Marie-Laure Thiolat; Celine Véga; Massimo Carella; Manolo Carta; Fabrizio Gardoni; Paolo Calabresi; Loredano Pollegioni; Erwan Bezard; Lucilla Parnetti; Francesco Errico; Alessandro Usiello
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.